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Abstract
Background: Type I interferons play important roles in innate immune defense. In HIV infection, type I interferons may delay
disease progression by inhibiting viral replication while at the same time accelerating disease progression by contributing
to chronic immune activation.
Methods: To investigate the effects of type I interferons in HIV-infection, we obtained cryopreserved peripheral blood
mononuclear cell samples from 10 subjects who participated in AIDS Clinical Trials Group Study 5192, a trial investigating
the activity of systemic administration of IFNa for twelve weeks to patients with untreated HIV infection. Using flow
cytometry, we examined changes in cell cycle status and expression of activation antigens by circulating T cells and their
maturation subsets before, during and after IFNa treatment.
Results: The proportion of CD38+HLA-DR+CD8+ T cells increased from a mean of 11.7% at baseline to 24.1% after twelve
weeks of interferon treatment (p=0.006). These frequencies dropped to an average of 20.1% six weeks after the end of
treatment. In contrast to CD8+ T cells, the frequencies of activated CD4+ T cells did not change with administration of type I
interferon (mean percentage of CD38+DR+ cells=2.62% at baseline and 2.17% after 12 weeks of interferon therapy). As
plasma HIV levels fell with interferon therapy, this was correlated with a ‘‘paradoxical’’ increase in CD8+ T cell activation
(p,0.001).
Conclusion: Administration of type I interferon increased expression of the activation markers CD38 and HLA DR on CD8+ T
cells but not on CD4+ T cells of HIV+ persons. These observations suggest that type I interferons may contribute to the high
levels of CD8+ T cell activation that occur during HIV infection.
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Introduction
HIV-1 infection is characterized by progressive CD4+ T
lymphocytopenia. The mechanisms driving this progressive loss
of CD4+ T-cells are not completely understood. Several studies
have found that increased T cell activation [1–3] and turnover
[4–9] predicts risk of disease progression in HIV infection [10–13].
Potential drivers of cellular activation and turnover in chronic
HIV infection include the type I interferons. Type I interferons
play an important role in innate and adaptive immune defenses
against viral replication and in immune cell maturation [14,15]. In
HIV infection, although interferon levels in blood have been
difficult to detect and may vary with the stage of infection [16],
interferon exposure is implicated, as microarray studies have
shown substantial upregulation of interferon stimulated gene
expression [17–21]. Type 1 interferons can induce cellular
resistance to HIV propagation as well as enhanced cytolytic
defenses [22–28].
The antiviral activities of type I interferons have been
exploited for the systemic treatment of hepatitis B and C
infection [29]. AIDS Clinical Trial Group (ACTG) Study 5192
was designed to evaluate the safety and antiretroviral activity of
type I interferon administrationi nc h r o n i cH I Vi n f e c t i o n .W e
decided to use this opportunity (through ACTG New Works
Concept Sheet 289) to investigate the effects of exogenous type I
interferon administration on indices of immune activation and
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particularly natural killer cell frequency in HIV-infected persons.
We found that systemic administration of interferon-alpha
induces phenotypic markers of immune activation (CD38 and
HLA-DR) on CD8+ T cells, but not on CD4+ T cells. We also
saw a tendency for CD4+ central memory T cells to enter cell
cycle during interferon therapy, although this trend did not
reach statistical significance.
Methods
Study Population
These studies were approved by the institutional review boards
at University of California, Davis, Northwestern University and
Duke University. De-identified stored specimens were examined at
Case Western Reserve University. Before study initiation, all study
participants provided written informed consent by. All clinical
investigation was conducted according to the principles expressed
in the Declaration of Helsinki.
In order to investigate the effects of interferon in HIV-infection,
we obtained cryopreserved peripheral blood mononuclear cell
(PBMC) samples from AIDS Clinical Trial Group (ACTG) study
5192 (n=13, Table 1), a trial investigating the activity of systemic
administration of type I interferon to persons with untreated HIV
infection. In this open label study, patients received 12 weekly
intramuscular injections of 180 ug of pegylated IFN-alpha 2a
(Genentech (Roche), San Francisco, CA) and were then followed
for 6 weeks after interferon treatment ended. Patients eligible to
enroll in ACTG 5192 had a CD4+ T cell count of .300 cells/ul,
had a plasma HIV-1 RNA level .5000 copies/ml, were
antiretroviral therapy-naı ¨ve or had not received antiretroviral
therapy for at least twelve weeks, had no evidence of infection with
hepatitis B or C virus and had serum transaminase levels no
greater than grade 1 by ACTG toxicity tables at entry. Exclusion
criteria included a history of severe psychiatric illness or a history
of chronic illness that could be worsened by interferon therapy
[21].
Peripheral blood mononuclear cells (PBMC) were prepared and
viably cryopreserved before the interferon treatment was initiated
(week 0), during the course of treatment (weeks 3 and 12), and 6
weeks after treatment was completed (week 18). For studies
involving natural killer (NK) cells, samples were obtained at Rush
Medical Center from five healthy donors not known to be HIV
infected.
Immunologic Analyses
Cryopreserved PBMC were thawed and stained with fluoro-
chrome-labeled monoclonal antibodies for flow cytometric anal-
yses. Allophycocyanin (APC) anti-CD4, Peridinin-cholorphyll
protein (PerCP) anti-CD8, Fluorescein isothiocyanate (FITC)
anti-HLA-DR, Phycoerythrin (PE) anti-CD38, FITC anti-
CD45RA, PE-Cyanin 7 (PE-Cy7) anti-CCR7, Pacific Blue anti-
CD4, APC anti-CD27 were purchased from Becton Dickinson
Biosciences (San Jose, CA). Fluorochrome-matched isotype control
antibodies were used to establish background staining and gating.
For examination of intracellular Ki-67 expression, samples were
fixed and permeabilized using a commercial kit (Cytofix
CytoPerm, Becton Dickinson Biosciences) and then stained with
PE-anti-Ki67 (Becton Dickinson, San Jose, CA) at 4uC for 30 min.
Fluorochrome-matched isotypes were used to establish back-
ground staining and proper gating of cells expressing this marker.
Weexamined indices of immune activation by studying cell cycling
(Ki-67 expression), expression of activation antigens (CD38 and
HLA-DR), and survival of phenotypically-defined central memory
CD4+ T cells. Central memory cells were defined as CD
27+CD45RA2 and CCR7+,n a ı ¨v ec e l l sa sC D 2 7 +, CD45RA+,
and CCR7+, transitional memory cells as CD27+,C D 4 5 R A 2,a n d
CCR72, and effector memory cells as CD272, CD45RA2,a n d
CCR72. We gated for live lymphocytes based upon cell size and
granularity, and we aimed to collect a million events (a minimum of
100,000 events were counted for each sample) using an LSR II flow
cytometer (Becton Dickinson). For examination of natural killer cell
frequency, cryopreserved PBMCs were thawed and cultured
overnight in RPMI 1640 (BioWhittaker, Walkersville, MD) supple-
mented with 10% heat-inactivated fetal bovine serum (GemCell),
100 U/mL penicillin, 100 ug/mL streptomycin (Sigma, St. Louis,
MO) and 2 mM L-glutamine (Sigma). PBMCs were washed,
resuspended in phosphate buffered saline (PBS) containing 0.5%
bovine serum albumin (Sigma) and 0.1% sodium azide (FACS
buffer), and stained for viability using AquaLiveDead (Invitrogen,
Carlsbad, CA). Nonspecific antibody binding to Fc receptors was
blocked by incubation of the cells with Fc-receptor blocking reagent
(Miltenyi Biotec, Auburn, CA). PBMCs were then surface stained
with the following antibodies: anti-CD3 Pacific Blue, anti-CD14
Pacific Blue, and anti-CD16 Pe-Cy7 (BD Pharmingen). In addition,
anti-CD19 Pacific Blue (Biolegend), anti- CD56 FITC (BD
Biosciences), and anti-CD69 APC (BD Biosciences) were used. After
incubation, cells were washed with FACS buffer, fixed with 2%
formaldehyde, and stored at 4uC until analysis on a BD LSRII flow
Table 1. Patient Cohort from AIDS Clinical Trial Group Study 5192.
Patient ID Sex Age CD4+ T Cell Count (cells/ul) PlasmaHIV RNA (log10 copies/mL)
1 M 35 367.5 4.37
2 M 45 480 4.49
3 M 37 929.5 4.10
4 M 46 650 3.57
5 M 37 372 4.39
6 M 42 325.5 4.72
7 M 30 298 3.86
8 M 32 612 3.84
9 M 45 359.5 4.76
10 F 36 510 4.56
doi:10.1371/journal.pone.0030306.t001
Inteferon a, HIV and T Cell Activation
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lymphocytes, and the different NK cell populations CD56dimCD16-
neg, CD56brightCD16neg, CD56dimCD16pos, CD56brightCD16-
neg,andCD56negCD16poswereanalyzedusingFACSDivaversion
6.1.1 software.
Statistical Methods
We used conventional measures of central location and spread
to describe the data. We used the Wilcoxon signed-ranks test for
bivariate comparisons of readouts at different timepoints. To assess
increasing or decreasing trends during the interferon treatment
period, we fitted repeated-measures general linear models for each
readout during the on-interferon period, and we used mixed
effects models to assess the contribution of multiple readouts to
changes in immune activation during the study period. Data were
analyzed using SPSS Statistics v. 20.0, IBM Corp, Somers, NY
and Stata MP v. 11.1, Stata Corp, College Station, TX. All tests of
hypothesis are 2-sided without formal correction for multiple
comparisons, and a p-value of #0.05 was considered significant.
Results
ACTG 5192 enrolled thirteen HIV-1 infected volunteers. Two
participants discontinued therapy during the course of the trial
[21]. We were able to study samples obtained from ten of the
eleven patients who completed the trial. One sample could not be
analyzed due to poor cell viability. Table 1 shows the baseline
characteristics of the ten participants we studied.
Effects of interferon therapy on circulating CD4 and CD8
T cell numbers and plasma HIV RNA levels
Over the course of interferon therapy, there was no significant
change in the numbers of circulating CD4 and CD8 cells at the
time points studied (Figure 1). There were, however, significant
increases in CD4+ T cell percentages early in treatment during
weeks 2 and 4 when the greatest declines in plasma HIV levels
were observed [21]. As previously reported [21], plasma HIV
RNA levels decreased significantly from week 0 (24,024 copies/
mL) to week 3 (3,142 copies/mL) (p=0.02) and from week 0 to
week 12 (8090 copies/mL) (p=0.039) during interferon therapy,
and there was a significant increase (p=0.02) in HIV RNA levels
to 28,772 copies/mL six weeks after therapy was stopped.
CD4+ T cell Maturation Subsets
At baseline, 45% of CD4 T cells were phenotypically naı ¨ve,
20% were central memory cells, 13% were transitional memory
cells and 7 percent were effector memory cells. Administration of
interferon-a did not alter the proportions of CD4+ T cell
maturation subsets (Table 2).
Indices of Immune Activation
Activation and turnover of T cells has been implicated as central
to the pathogenesis of immune deficiency in HIV infection
[4,9,30–32]. Since expression of activation markers CD38 and
HLA-DR on circulating T cells is a validated predictor of disease
progression in chronic HIV-1 infection [10], we asked if interferon
exposure would increase expression of one or both of these
markers in vivo as it does in vitro [33]. The proportion of CD8+ T
cells that co-expressed CD38 and HLA-DR tended to increase
during interferon administration from a median of 11.7% at
baseline to 18.2% after three weeks of interferon treatment
(p=0.093) and increased significantly to 24.1% after twelve weeks
of interferon treatment (p=0.011). The proportion of CD8+ T
cells co-expressing CD38 and HLA-DR dropped to 20.1% six
weeks after treatment was terminated, and this was not
significantly different from baseline (p=0.214) (Figure 2).
The proportions of CD8+ T cells that were HLA-DR+ but
CD382 decreased from a median of 34.8% to 28.7% after three
weeks of interferon treatment (p=0.009) and to 23.0% after
Figure 1. CD4+ and CD8+ T cell counts. The CD4 Cell Count (A) and
the CD8 Cell Count (B) are portrayed over the course of interferon-alpha
treatment during the ACTG 5192 Study. Week 0 corresponds to the
patients’ baseline cell counts before beginning Interferon-Alpha
Therapy. Weeks 3 and 12 correspond to 3 weeks and 12 weeks of
interferon-alpha Therapy. Interferon-Alpha therapy was stopped at
Week 12, and therefore Week 18 corresponds to 6 weeks off therapy.
doi:10.1371/journal.pone.0030306.g001
Table 2. CD4+ T cell Dynamics.
Week 0 Week 3 Week 12 Week 18
Central Memory T cells 20% 19% 22% 20%
Naive T cells 45% 43% 44% 46%
Transitional Memory T cells 13% 13% 16% 15%
Effector Memory T cells 7% 6% 5% 5%
The proportions of CD4+ T cell maturation subsets are shown over the course of
interferon-alpha treatment during the ACTG 5192 Study. Central memory cells
were defined as CD27+CD45RA2 and CCR7+, whereas naı ¨ve cells are CD27+,
CD45RA+, and CCR7+, transitional memory cells are CD27+, CD45RA2,a n d
CCR72, and effector memory cells are CD272, CD45RA2, and CCR72. Week 0
corresponds to the patients’ baseline cell counts before beginning Interferon-
Alpha Therapy. Weeks 3 and 12 correspond to 3 weeks and 12 weeks of
interferon-alpha therapy. Interferon-Alpha therapy was stopped at Week 12,
and therefore Week 18 corresponds to 6 weeks off therapy.
doi:10.1371/journal.pone.0030306.t002
Inteferon a, HIV and T Cell Activation
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to a median of 38.9% six weeks after treatment ended, which was
not a significant change from baseline (p=0.139). The increase in
the proportion of activated (CD38+ HLA-DR+) CD8 cells
appeared to be a result of increasing expression of CD38 on
CD8 T cells that were already expressing HLA-DR. The
proportions of CD8+ T cells that were HLA-DR+ had a non-
significant decrease from a median of 55.3% to 50.3% after three
weeks of treatment (p=0.1602) and stayed relatively stable at
51.2% after twelve weeks of treatment (p=0.2031). The median
proportion of HLA-DR+ cells increased to a median of 62.3% six
weeks after treatment ended (p=0.055).
Interferon therapy did not increase significantly the proportions
of CD8+ T cells expressing CD38 in the absence of HLA-DR, as
the median proportion of these cells was 3.7% at baseline and
5.0% after three weeks of interferon treatment (p=0.169) and
6.1% after twelve weeks of treatment (p=0.214). These frequen-
cies tended to fall to a median of 1.2% six weeks after treatment
ended (p=0.086 when compared to baseline).
In contrast to our findings for CD8+ T cells, the frequencies of
activated CD4+ T cells did not change with administration of type
I interferon (median percentage of CD38+DR+ cells=2.6% at
baseline and 2.2% after 12 weeks of interferon therapy). A non-
significant increase in this frequency to a median of 5.6%
(p=0.374 when compared to baseline) was seen 6 weeks after
interferon treatment was stopped (Figure 2). Therapy was also not
associated with an increase in single positive (CD38+) or (HLA-
DR+) CD4 T cells.
To further delineate the effect of interferon on activation indices
given the effects of interferon on both viremia and CD8+ T cell
activation, we fitted mixed effects models to assess the contribution
of viremia reduction on immune activation indices. We found that
the magnitude of change in activation during interferon treatment
was significantly associated with the change in viremia during the
same period (p,0.001).
Cell Cycling
Since the activation and turnover of CD4+ T cells and
especially central memory CD4+ T cells is thought to play a
critical role in the progressive immune deficiency of HIV infection,
we identified the proportion of cells in CD4+ T cell maturation
subsets that were in cell cycle by staining for intra-nuclear
expression of Ki-67 at baseline, 3 weeks of therapy, 12 weeks of
therapy, and 6 weeks after interferon treatment was ended.
When the expression of Ki-67 was evaluated among all
circulating CD4+ T cells, there was no indication that this
population as a whole was driven into cell cycle by interferon
therapy. The proportion of Ki67+ CD4+ T cells remained stable
throughout the study period (median values of 1.6% at baseline,
1.2% after three weeks of therapy, 0.9% after twelve weeks of
therapy, and 0.9% six weeks after the end of therapy) (Figure 3).
Nonetheless, when expression of Ki-67 was evaluated among
defined CD4+ T cell maturation subsets, there was indication that
exogenous interferon differentially regulated cycling of cells in
these subsets. Interferon therapy tended to increase the proportion
of Ki-67+ cells in central memory CD4+ T cells from 1.1% at
baseline to 2.4% at week 3 (p=0.176) and 1.9% at week 12
(p=0.091, (Figure 4), although these trends failed to reach
statistical significance. The proportion of Ki67+ CD4+ naı ¨ve cells
at baseline was very low and remained low throughout therapy.
The proportions of Ki67+ CD4+ effector memory and transitional
memory T cells remained stable throughout the twelve weeks of
interferon therapy.
Natural Killer Cells
Natural killer cells respond to interferon-alpha with increased
cytolytic capability [27,28] even in HIV- infected patients [34,35].
Here we asked if interferon-alpha treatment had any affect on
circulating NK cell frequencies. The percentage of CD56bright
CD16dim NK cells in HIV-infected patients at baseline was not
significantly different from what was seen among healthy donors.
Interferon-alpha treatment led to a slight increase in the
Figure 2. Co-expression of CD38 and HLA-DR on CD4+ and
CD8+ T cells. The percentage of CD4+ T cells (A) and CD8+ T cells (B)
co-expressing CD38 and HLA-DR is shown over the course of interferon-
alpha treatment during the ACTG 5192 Study. Week 0 corresponds to
the patients’ baseline cell counts before beginning Interferon-Alpha
Therapy. Weeks 3 and 12 correspond to 3 weeks and 12 weeks of
interferon-alpha Therapy. Interferon-Alpha therapy was stopped at
Week 12, and therefore Week 18 corresponds to 6 weeks off therapy.
The bar represents the median value.
doi:10.1371/journal.pone.0030306.g002
Inteferon a, HIV and T Cell Activation
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changes were not statistically significant. The proportion of
CD56dimCD16pos NK cells in the infected individuals at baseline
was significantly (p=0.004) lower (30%) than among seronegative
donors. Interferon treatment did not affect these proportions
during the course of treatment. In addition, CD56negCD16pos
NK cells were present in the infected subjects even though they
were absent in the seronegative donors, as expected [36].
Interferon-alpha treatment did not affect the percentage of
CD56negCD16pos NK cells. In summary, we could find no effect
of interferon alpha administration on the proportions of NK cells
or their subsets in HIV infection (not shown).
Discussion
The role and effects of type I interferons in chronic HIV infection
arenot fullyunderstood.Ontheonehand,IFN-aeffectivelyinhibits
viral replication [22–26,37–40]; on the other hand, high level
expression of IFN-a could plausibly drive disease progression by
activating, exhausting and depleting CD4+ T cells [34–37,41–44].
WhileinsomeinvitromodelsIFN-acandriveCD4+T cellapoptosis
and death by upregulating TNF related apoptosis inducing ligand
(TRAIL) expression in CD4+ cells [41–44], in others IFN-a may
protect T cells from apoptosis [33,45–48]. We have recently
reported that interferon-a may protect T cells from apoptosis in vitro
[33], conceivably through mechanisms related to upregulation of
survival genes [45–47]. Thus, the in vivo effects of interferon-a may
be complex and difficult to predict.
As reported in the primary publication of this study [21],
systemic administration of type I interferon resulted in suppression
of HIV replication as had been seen in previous studies [22–26].
The goal of this substudy was to examine the immunologic effects
of type I interferon administration to persons with chronic HIV
infection and without HCV co-infection. In earlier studies,
decreases in absolute CD4+ T cell counts were seen during
interferon administration, but we found no significant change in
CD4+ T cell numbers over twelve weeks of interferon therapy.
This differs from results of earlier studies, which showed
diminished cell counts in subjects with Kaposi’s sarcoma (and
presumably co-infected with HHV-8) during IFN-a therapy [49–
51]. One of the major differences between this study and the
earlier studies was the use of peglyated interferon alpha-2a
Pegylated interferon-a has an increased half-life, providing a
longer antiviral effect than the nonpegylated forms [52,53].
Pegylated interferon alpha- 2a also has a more favorable safety
profile than the previously available interferon-alpha formulations
[54]. Conceivably, the stability in CD4+ T cell counts we observed
may be attributable to differences in disease stage during the
clinical trials, as well as the more stable pharmacodynamics of this
drug.
High level T cell activation, as reflected in increased surface
expression of CD38 and HLA-DR on both CD4+ and CD8+ T
cells, is characteristic of untreated HIV infection [1–4,10–13].
Treatment with combination antiretroviral therapy characteristi-
cally results in prompt and substantial decreases in indices of
immune activation [55,56]. Although this study was small, we
found no evidence for a decrease in any of the activation indices
we measured. In a study of 11 patients with an average decrease in
plasma viremia of 1 log10 after antiretroviral therapy, a significant
and persistent decrease in immune activation was noted as soon as
2 weeks after treatment initiation that persisted for at least 12
weeks [57]. Yet in this study, with administration interferon-a and
an approximate1 log10 decrease in plasma HIV RNA levels, we
saw no decrease in immune activation indices. To the contrary, we
found that systemic administration of type I interferon to persons
with untreated HIV infection resulted in increased expression of
the activation marker CD38 on CD8+ T cells but not on CD4+ T
cells. We did not observe increases in the expression of HLA-DR
among either CD4+ or CD8+ T cells. In earlier work, we had
found that in vitro exposure to interferon-alpha increased surface
expression of CD38 on CD8+ T cells but not CD4 T+ cells [33].
We had also found a significant decrease in the proportion of
CD382 HLA-DR+ CD8+ T cells during treatment with
interferon-a. Several earlier reports have linked the frequency or
function of CD382 HLA-DR+ CD8 T cells to a favorable
outcome in HIV infection [58–60]. These observations suggest
that increased endogenous expression of type I interferons may
contribute to the high levels of CD38 expression on CD8+ T cells
that are characteristic of HIV infection and are recognized
predictors of disease progression [10], but that other phenotypic
markers of immune activation seen in HIV infection may not be
attributable directly to type I interferon exposure.
We found a trend towards increases in proportions of
phenotypically defined central memory CD4+ T cells that were
in cell cycle during administration of interferon-alpha. Turnover
and cycling of central memory CD4+ T cells is thought to be a
critical determinant and predictor of outcome in chronic HIV and
SIV infection [9,30–32]. With only 10 subjects studied, we may
have been underpowered to reveal a significant increase in cell
cycling with interferon therapy. A very modest increase in naı ¨ve
CD4+ T cell cycling also was observed, but the numbers of cycling
naı ¨ve cells was too low to evaluate quantitative differences in
cycling over the course of the study. There is reason to suspect that
some effects of exogenous interferon administration in HIV
infection might be attenuated as a result of diminished
responsiveness to type I interferon, as we had earlier found that
monocytes in HIV infection had both decreased type I interferon
receptor expression and decreased signaling after interferon
exposure [61]. Thus, even a modest effect of exogenous type I
interferon on phenotypic indices of immune activation and cell
Figure 3. Cell cycle status of CD4+ T cells. The cell cycle status of
CD4+ T cells as measured by Ki-67 expression is shown over the course
of interferon-alpha treatment during the ACTG 5192 Study. Week 0
corresponds to the patients’ baseline cell counts before beginning
Interferon-Alpha Therapy. Weeks 3 and 12 correspond to 3 weeks and
12 weeks of interferon-alpha Therapy. Interferon-Alpha therapy was
stopped at Week 12, and therefore Week 18 corresponds to 6 weeks off
therapy. The bar represents the median value.
doi:10.1371/journal.pone.0030306.g003
Inteferon a, HIV and T Cell Activation
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type I interferon exposure that is suggested by the demonstrable
and broad upregulation of interferon responsive genes in chronic
HIV infection [17,20].
Our findings suggest that type I interferon may contribute to the
heightened immune activation profile seen in chronic HIV
infection but that the activation phenotype in chronic infection
is not precisely recapitulated by systemic interferon administration.
While some of this may be related to relative refractoriness to
additional interferon stimulation, it is also possible that other
factors may also contribute to the increased immune activation
profile that is characteristic of untreated HIV infection. Some of
this may be a consequence of HIV replication itself [62–66], or
increased antigenic stimulation by HIV peptides or by peptides of
other microbes that have been permitted to replicate in the setting
of HIV related immune deficiency [62–67]. Indeed, our findings
suggest that the effect on interferon on CD8+ T cell activation
mirrors and may be related to interferon-induced decreases in
plasma viremia. We propose that the equilibrium between
endogenous interferon levels in response to HIV replication was
perturbed by our treatment strategy such that a decrease in HIV
levels induced by exogenous interferon resulted in a ‘‘paradoxical’’
increase in immune activation as viremia fell. Recent work by
members of our group and others has implicated translocation of
microbial products across the damaged gut mucosa as an
important driver of immune activation and inflammation in
chronic HIV infection [49–54,68–73]. While type I interferons are
inducible by these microbial TLR agonists [74], broad induction
of a variety of inflammatory cytokines [75] is also an expected
outcome of systemic exposure to microbial products, and these
cytokines may also contribute to immune activation in HIV
infection.
In summary, exogenous administration of interferon-alpha to
HIV-infected persons can recapitulate and/or exacerbate certain
but not all immunophenotypic abnormalities characteristic of
untreated HIV infection. It is likely that other factors also
contribute to the activation/inflammatory phenotype that char-
acterizes untreated HIV infection.
Figure 4. Cell cycle status of CD4+ T cell maturation subsets. The cell cycle status of CD4+ T cell maturation subsets, Central Memory CD4 +T
Cells (A), Naive CD4+ T cells (B), Transitional Memory CD4+ T cells (C), and Effector Memory CD4+ Tcells (D), is shown over the course of interferon-
alpha treatment during the ACTG 5192 Study. Central memory cells were defined as CD 27+CD45RA2 and CCR7+, whereas naı ¨ve cells are CD27+,
CD45RA+, and CCR7+, transitional memory cells are CD27+, CD45RA2, and CCR72, and effector memory cells are CD272, CD45RA2, and CCR72.
Week 0 corresponds to the patients’ baseline cell counts before beginning Interferon-Alpha Therapy. Weeks 3 and 12 correspond to 3 weeks and 12
weeks of interferon-alpha therapy. Interferon-Alpha therapy was stopped at Week 12, and therefore Week 18 corresponds to 6 weeks off therapy. The
bar represents the median value.
doi:10.1371/journal.pone.0030306.g004
Inteferon a, HIV and T Cell Activation
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